An orally active dual CysLT1 and CysLT2 antagonist possessing a distinctive structure which consists of triple bond and dicarboxylic acid moieties is described. Gemilukast (ONO-6950) was generated via isomerization of the core indole and the incorporation of a triple bond into a lead compound. Gemilukast exhibited antagonist activities with IC50 values of 1.7 and 25 nM against human CysLT1 and human CysLT2, respectively, and potent efficacy at an oral dose of 0.1 mg/kg given 24 h before LTD4 challenge in a CysLT1-dependent guinea pig asthmatic model. In addition, gemilukast dose-dependently reduced LTC4-induced bronchoconstriction in both CysLT1- and CysLT2-dependent guinea pig asthmatic models, and it reduced antigen-induced constriction of isolated human bronchi. Gemilukast is currently being evaluated in phase II trials for the treatment of asthma.
Furan derivatives R 0060Enantioselective Synthesis of a 3,5,5-Trialkylated Tetronic Acid Derivative. -A multi-step enantioselective procedureallows the synthesis of the tetronic acid derivative (XV) via Dieckmann condensation of ester (XI) as a key step. This approach realizes access to the tetronic acid moiety of the acylphloroglucinol-type natural product perforatumone. -(TAKAO*, K.-I.; KOJIMA, Y.; MIYASHITA, T.; YASHIRO, K.; YAMADA, T.; TADANO, K.-I.; Heterocycles 77 (2009) 1, 167-172; Dep. Appl.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.